Wednesday, 08 April 2020

Mitsubishi Tanabe, Cytochroma end agreement

06 June 2012 | News | By BioSpectrum Bureau

Mitsubishi Tanabe, Cytochroma terminate agreement

Mitsubishi Tanabe will return the rights of MT-2832 to Cytochroma

Mitsubishi Tanabe will return the rights of MT-2832 to Cytochroma

Singapore: Japanese company Mitsubishi Tanabe Pharma and Canada-based Cytochroma have terminated a license agreement executed in 2008.

The two companies have mutually agreed to the termination of a license agreement that granted Mitsubishi Tanabe an exclusive agreement to develop MT-2832 (lunacalcipol), a novel vitamin D compound, as a treatment for secondary hyperparathyroidism in dialysis patients.

Under the agreement, Mitsubishi Tanabe had license to MT-2832 in the US and Asia, including Japan. Upon termination of the agreement, Mitsubishi Tanabe will return the rights of MT-2832 to Cytochroma.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account